Product information and disease description Product description Product information

Average sales price and wholesale acquisition cost

5 evidence topics · 3 sources

Wholesale acquisition cost published at or after approval

No evidence found.

Pre-approval market research assumption for the monthly wholesale acquisition cost: AiCuris corporate presentation, August 2025

“Monthly per-patient WAC in US~$30K” (opens the source at this quote in a new tab)
“(assumes 28-day treatment course)” (opens the source at this quote in a new tab)
“Market research suggests up to 2bn annual peak sales for acute therapy with Pritelivir” (opens the source at this quote in a new tab)
“Large Scale Market Research with ~800 Health Care Professionals (HCP) was conducted in 3 waves” (opens the source at this quote in a new tab)

Company sales expectations: Asahi Kasei, February and April 2026

“Pritelivir is anticipated to address approximately 15,000 immunocompromised patients in the U.S. and is projected to achieve meaningful penetration in the second-line setting, potentially approaching 70%, subject to market conditions.” (opens the source at this quote in a new tab)
“Peak revenue from pritelivir is projected to exceed $400 million in the mid- to late 2030s.” (opens the source at this quote in a new tab)

“Market research suggests that prescribing will likely shift significantly toward pritelivir compared to the existing drug foscarnet, which requires intravenous infusion at hospitals, since pritelivir is administered orally once daily.” (opens the source at this quote in a new tab)
“However, market research for new drugs often shows higher prescription intent than actual clinical adoption. Taking this into account, we set the prescription share target conservatively at 70%.” (opens the source at this quote in a new tab)

Difference between the AiCuris and Asahi Kasei sales assumptions

“In previously published materials from Aicuris, assumptions were presented indicating a 75% prescription share and peak sales of $2 billion.” (opens the source at this quote in a new tab)
“This discrepancy arises because Aicuris' previously disclosed sales assumptions included revenues from markets outside the U.S., whereas our projections do not incorporate such international sales.” (opens the source at this quote in a new tab)
“Additionally, Aicuris' prior assumptions included sales potential from expanding the indication to a broader population of general HSV infection patients, whereas we calculated the market size primarily targeting immunocompromised patients.” (opens the source at this quote in a new tab)

Company statement on prices outside the United States

“If drug prices were set significantly lower outside the U.S., this could lead to substantial reductions in U.S. drug prices as well.” (opens the source at this quote in a new tab)

Royalties on United States sales

“No royalty payments to third parties are required for the U.S. launch.” (opens the source at this quote in a new tab)

Average sales price

Not applicable.